NCT06864221 Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
| NCT ID | NCT06864221 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 260 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 260 participants in total. It began in 2024-09-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Plasma contains a variety of metabolites, among which sphingolipids, including ceramide, sphingosine, and sphingosine-1-phosphate, serve as important intracellular second messengers and are involved in various cellular signaling pathways, such as apoptosis. We hypothesize that plasma sphingolipid levels may be associated with the efficacy of radiotherapy for liver cancer. This study will utilize LC-MS/MS technology for qualitative and quantitative analysis of plasma sphingolipids in liver cancer patients undergoing radiotherapy. Clinical data related to patient prognosis will also be collected to investigate the correlation between plasma sphingolipid levels and the therapeutic efficacy of liver cancer radiotherapy. The aim is to establish the clinical diagnostic significance of plasma sphingolipid levels in predicting the efficacy of liver cancer radiotherapy, providing new insights to enhance the effectiveness of radiotherapy in liver cancer treatment.
Eligibility Criteria
Inclusion Criteria: * Patients voluntarily signed the informed consent form. * Aged between 18 and 80 years. * Clinically diagnosed with primary liver cancer according to the latest treatment guidelines. * Determined by the treating physician to require radiotherapy. * Expected survival time of more than 3 months. Exclusion Criteria: * Patients who discontinued radiotherapy or did not complete the planned treatment. * Presence of malignancies from other origins. * Severe metabolic diseases such as uncontrolled diabetes, significant obesity, or fatty liver disease. * Uncontrolled comorbidities, such as severe cardiovascular or pulmonary diseases, that may affect treatment or study outcomes.
Contact & Investigator
Yiyi Li, PhD
PRINCIPAL INVESTIGATOR
Nanfang Hospital, Southern Medical University
Frequently Asked Questions
Who can join the NCT06864221 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06864221 currently recruiting?
Yes, NCT06864221 is actively recruiting participants. Contact the research team at liiyiiyii@163.com for enrollment information.
Where is the NCT06864221 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06864221 clinical trial?
NCT06864221 is sponsored by Nanfang Hospital, Southern Medical University. The principal investigator is Yiyi Li, PhD at Nanfang Hospital, Southern Medical University. The trial plans to enroll 260 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.